Market Trends– category –
-
Biotech M&A Heats Up: Merck KGaA Acquires Bio-Techne for $11.3B to Bolster Life Science Tools for Cell and Gene Therapy
Fintent United States Overview Fintent's September 8, 2026, report forecasts intensified M&A activity in healthcare and life sciences, highlighting Merck KGaA's $11.3 billion acquisition of Bio-Techne. This strategic move aims to str... -
Cell Therapy Startups Exceed $36 Billion in Cumulative Fundraising, Top Companies Secure Over $1 Billion Each
New Market Pitch United States Overview A report by New Market Pitch reveals that cell therapy startups have collectively surpassed $36 billion in cumulative fundraising by 2026, with leading companies each raising over $1 billion. The a... -
CAR T-Cell Therapy Clinical Trial Landscape for Non-Hodgkin Lymphoma Expands with Over 70 Companies Developing Next-Gen Treatments
GlobeNewswire Global Overview A report by DelveInsight, released via GlobeNewswire, offers a detailed analysis of the CAR T-cell therapy clinical trial landscape for Non-Hodgkin Lymphoma (NHL). The report highlights over 70 companies adv... -
Global Cell and Gene Therapy Manufacturing Services Market to Surge to $31.3 Billion by 2035, Driven by Regulatory Modernization
openPR.com (DataM Intelligence) Global Overview According to DataM Intelligence, the global cell and gene therapy manufacturing services market is projected to reach $8.77 billion in 2026, growing rapidly to $31.3 billion by 2035 with a ... -
2026 iPSC Industry Report: Allogeneic Therapies Surpass Autologous, Diabetes, Parkinson’s, AMD Clinical Trials Progress
BioInformant Global Overview The 2026 iPSC Industry Report by BioInformant details advancements in iPSC technology for therapeutic applications, disease modeling, drug discovery, personalized medicine, and toxicity testing. Notably, allo... -
Cell and Gene Therapy GMP Services Market Forecast to Reach $5.88 Billion by 2030, Growing at 18.9% CAGR
The Business Research Company Global Overview The Business Research Company released a report forecasting the GMP services market for cell and gene therapy to reach $2.95 billion in 2026 and expand to $5.88 billion by 2030, exhibiting an... -
Exosome Therapy Revolutionizes Skin Treatment: Promotes Cell Regeneration and Anti-Inflammation Without Physical Injury
Dr Azra Vaziri USA Overview Exosome therapy harnesses tiny extracellular vesicles secreted by stem cells to deliver biological signals for cell repair and regeneration to skin cells. Unlike traditional dermapen or microneedling, this tre... -
The Next Frontier in Hematology: China’s Leadership in CAR-T and CRISPR Gene Editing
Source unknown China Overview China has rapidly emerged as a global leader in hematology, achieving significant breakthroughs in CAR-T cell therapy and CRISPR-based hematopoietic stem cell editing. This rapid ascent is profoundly reshapi... -
Rewriting Sickle Cell Disease: The Promise of In Vivo Gene Editing and the Global Equity Challenge
Current Opinion in Hematology USA Overview The quest to cure sickle cell disease (SCD) hinges on establishing durable, healthy hematopoiesis without significant toxicity. While cutting-edge in vivo and prenatal hematopoietic stem cell (H... -
Watchmaker Genomics Bolsters Global Supply Chain, Doubles Manufacturing Capacity with 100,000 Sq Ft Boulder Facility
Longmont Times-Call USA Overview Life sciences firm Watchmaker Genomics Inc. has significantly expanded its global manufacturing capabilities by securing approximately 100,000 square feet of new production space in Boulder, Colorado. Thi...
